Cytek BiosciencesCTKB +0.54%71 Debt-to-Equity is 0.08 as of Mar. 2026, which is 100% above its 10-year median of 0.04. GuruFocus rates CTKB with a GF Score™ of 71/100 and a GF Value™ of $5.83 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 704 Medical Devices & Instruments companies, Cytek Biosciences ranks better than 72.73% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Cytek Biosciences's Debt-to-Equity or its related term are showing as below:
CTKB'
s Debt-to-Equity Range Over the Past 10 Years
Min: -0.18 Med: 0.04 Max: 0.08
Current: 0.08
During the past 7 years, the highest Debt-to-Equity Ratio of Cytek Biosciences was 0.08. The lowest was -0.18. And the median was 0.04.
CTKB's Debt-to-Equity is ranked better than 72.73% of 704
companies
in the Medical Devices & Instruments industry
Industry Median: 0.225
vs CTKB: 0.08
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Cytek Biosciences Debt-to-Equity Related Terms
Cytek Biosciences Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Cytek Biosciences's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CTKB vs CERS, NPCE, CLPT: Debt-to-Equity Comparison
For the Medical Devices subindustry, Cytek Biosciences's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cytek Biosciences Debt-to-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Cytek Biosciences's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Cytek Biosciences's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cytek Biosciences (CTKB) has a Debt-to-Equity of 0.08 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Cytek Biosciences and its competitors. This is 100% above median its historical median of 0.04. According to the industry distribution chart, Cytek Biosciences ranks #192 out of 704 companies in the Medical Devices & Instruments industry, placing it in the top 27.3%.
Is Cytek Biosciences' Debt-to-Equity too high?
Cytek Biosciences' current Debt-to-Equity of 0.08 is 100% above median its 10-year median of 0.04. The Medical Devices & Instruments industry median Debt-to-Equity is 0.23. Cytek Biosciences' value of 0.08 is 64.4% below this industry median. Based on the distribution chart, Cytek Biosciences ranks #192 out of 704 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Cytek Biosciences has a GF Score™ of 71/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Cytek Biosciences' Debt-to-Equity compare to CERS and NPCE?
According to the Medical Devices & Instruments industry distribution chart, Cytek Biosciences ranks #192 out of 704 companies for Debt-to-Equity. This puts Cytek Biosciences in the upper half of its industry. The industry median Debt-to-Equity is 0.23. Cytek Biosciences' value of 0.08 is 64.4% below this benchmark. While the company's 10-year median is 0.04 vs. the industry median of 0.23, Cytek Biosciences has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Devices & Instruments company?
The median Debt-to-Equity among Medical Devices & Instruments companies is 0.23, based on 704 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cytek Biosciences's current Debt-to-Equity of 0.08 is 64.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Cytek Biosciences and its competitors. For the Medical Devices & Instruments industry, the median Debt-to-Equity is 0.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cytek Biosciences's current Debt-to-Equity is 0.08, which is 100% above median its own 10-year median of 0.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cytek Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Cytek Biosciences (CTKB) is currently considered Modestly Undervalued. The stock's GF Value™ is $5.83, compared to a current price of $4.63 — trading 20.6% below its estimated fair value. The current Debt-to-Equity is 0.08, which is 100% above median its 10-year median of 0.04 and 64.4% below the Medical Devices & Instruments industry median of 0.23. Cytek Biosciences' overall GF Score™ is 71/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Cytek Biosciences (CTKB), the current Debt-to-Equity is 0.08 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cytek Biosciences (CTKB) Overvalued in 2026?
Based on GuruFocus' analysis, Cytek Biosciences stock appears to be undervalued.
The current stock price of $4.63 is trading 20.6% below its estimated GF Value™ of $5.83.
GuruFocus considers Cytek Biosciences to be Modestly Undervalued.
Key valuation signals for CTKB:
Debt-to-Equity: 0.08 (100% above median its 10-year median of 0.04)
GF Value™: $5.83 vs. price of $4.63 (20.6% below fair value)
Industry Position: 64.4% below the Medical Devices & Instruments median (#192 of 704)
No single metric tells the full story. See the CTKB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of research and clinical tools with its novel technical approach of leveraging the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its patented FSP technology optimizes sensitivity and accuracy through its optical and electronic designs that utilize an inventive method of light detection and distribution to a specifically selected number and type of detectors. Its FSP cell analyzers, the Cytek Aurora, Northern Lights, and Cytek Aurora Evo systems, deliver high-resolution, high-content and high-sensitivity cell analysis and address the inherent limitations of other technologies.
71GF Score
Get the complete analysis for CTKB
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CTKB has been successfully added to your 
